Sara Ward is a Dermatology physician affiliated with Temple University. OpenAlex indexes 82 publications with 2,014 citations (h-index 25).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20251 payment
- Regeneron Healthcare Solutions, Inc.Program year20251 payment
- Amgen Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
44.7%Azole Antifungal13.8%Ketoconazole100%Part D≥27 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor9.6%Valacyclovir100%Part D≥17 patients+ 3 more classes in this area
Dermatology
20.6%Corticosteroid13.8%Triamcinolone Acetonide70%Triamcinolone acetonide30%Part D + Part B≥33 patientsOther antifungals for topical use4.2%Ciclopirox100%Part D<11 patients+ 1 more class in this area
Sensory organs
10.8%Corticosteroid10.8%Clobetasol Propionate66%Desonide34%Part D≥20 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Paclitaxel-Associated Mechanical Sensitivity and Neuroinflammation Are Sex-, Time-, and Site-Specific and Prevented through Cannabigerol Administration in C57Bl/6 Mice
International Journal of Molecular Sciences
2024 - KLS-13019, a Novel Structural Analogue of Cannabidiol and GPR55 Receptor Antagonist, Prevents and Reverses Chemotherapy-Induced Peripheral Neuropathy in Rats
Journal of Pharmacology and Experimental Therapeutics
2024 - Epicutaneous Sensitization to the Phytocannabinoid β-Caryophyllene Induces Pruritic Inflammation
International Journal of Molecular Sciences
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Gerard Criner, MD
Temple University
Deborah Crabbe, MD
Temple University
Terry Heiman-Patterson, MD
Temple University
Michel Pontari, MD
Temple University
Robert Modlin, MD
University of California, Los Angeles
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Victoria Werth, MD
Perelman School of Medicine at the University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”